Laddar...

Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer

OBJECTIVE: Romidepsin (FK228) was recently approved by the FDA for the treatment of cutaneous and peripheral T cell lymphoma. We have shown in vitro efficacy of FK228 in ovarian cancer. Here, our goal was to evaluate FK228 combined with cisplatin in ovarian cancer in vitro and in vivo. METHODS: Ovar...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Wilson, Andrew J., Lalani, Anum S., Wass, Erika, Saskowski, Jeanette, Khabele, Dineo
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2012
Ämnen:
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3541411/
https://ncbi.nlm.nih.gov/pubmed/23010348
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2012.09.016
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!